BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Bacterial infections clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for bacterial infections: 252 (145 sponsors; 53 newly posted in the last 180 days, 5 stopped in the last 180 days; 28 new-entrant sponsors). Momentum score 19.8, rank 30 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 40, Phase 2 67, Phase 3 56, Phase 4 10, N/A 79.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Pfizer PFE14P3 7, P2 4, P1 1, NA 257
CanSino Biologics Inc.13NA 4, P2 1, P4 1, P1 3, P3 452
Incyte Corporation INCY6P3 4, P1 1, P2 102
Sinovac Biotech Co., Ltd SVA4P3 403
Novartis Pharmaceuticals NVS14NA 9, P3 3, P4 1, P1 134
Sanofi SNY6P2 2, P3 2, NA 1, P1 112
AbbVie ABBV5NA 1, P2 2, P3 202
Sinovac Life Sciences Co., Ltd.5P1 2, P3 2, P2 111
Basilea Pharmaceutica2P3 200
GlaxoSmithKline13P2 3, P1 7, NA 1, P3 1, P4 125
Institut Pasteur5NA 4, P3 112
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.2P1 1, P3 100
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd2P1 1, P3 100
Sanofi Pasteur, a Sanofi Company SNY2NA 1, P3 101
UCB Biopharma SRL2P1 1, P3 101
AVVA Pharmaceuticals Ltd.1P3 100
Baxis Pharmaceuticals, Inc.1P3 100
Beijing Minhai Biotechnology Co., Ltd1P3 100
Biofabri, S.L1P3 100
Bluefin Biomedicine, Inc.1P3 100
Chengdu CoenBiotech Co., Ltd1P3 100
China National Biotec Group Company Limited1P3 100
Grifols Therapeutics LLC GRFS1P3 100
ISTx, LLC new entrant1P3 110
Kaneka Americas Holding Inc.1P3 101

New-entrant sponsors: ISTx, LLC.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-24 est.P1/P2CanSino Biologics Inc.NCT07600983 Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)Streptococcus Pneumoniae Infectionrecruiting854
2026-12 est.P3Qilu Pharmaceutical Co., Ltd.NCT07089186 Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae InfectionsHospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Comprecruiting80
2026-12 est.P2Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.NCT07413094 Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDSSepsisrecruiting309
2026-12-30 est.P2/P3Beijing Continent Pharmaceutical Co, Ltd.NCT07388680 Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune PneumoniaRadiation-induced Lung Injury; Immune-related Pneumoniarecruiting298
2026-12-31 est.P3Materia Medica HoldingNCT06284265 Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial CystitisCystitis Chronic; Cystitis Bacterial; Recurrence of Chronic Bacterial Cystitisactive not recruiting415
2027-01 est.P2Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)NCT06672978 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including AcutAcute Pyelonephritis; Complicated Urinary Tract Infectionactive not recruiting66
2027-01-24 est.P2Chengdu Syncor Pharmaceutical Co., Ltd.NCT07483671 Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV PatientsBacterial Vaginosisnot yet recruiting80
2027-02-11 est.P2AstraZeneca AZNNCT07215702 A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.Sepsis; Acute Kidney Injuryrecruiting124
2027-02-15 est.P3CanSino Biologics Inc.NCT07017777 A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Pneumococcal Infections; Streptococcal Infections; Bacterial Infectionsactive not recruiting600

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-15 est.P2ImmunityBio, Inc. IBRXNCT07492888 Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)Acute Respiratory Distress Syndrome; Severe Community-Acquired Pneum; Sepsis; Lymphopenia / Immunopawithdrawn
2026-09-22P2Jiangsu HengRui Medicine Co., Ltd.NCT06841731 A Trial of HRS-8427 in the Treatment of Adults With Bacterial PneumoniaHospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP)completed120
2026-09-01P3Jiangsu HengRui Medicine Co., Ltd.NCT06569056 A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisComplicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)completed579
2026-09 est.P2Vasomune Therapeutics, Inc.NCT05123755 Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.Acute Respiratory Distress Syndrome; Viral or Bacterial Infections; Pneumonia; Pneumonia, Viral; Resactive not recruiting60
2026-08-03 est.P2Catalysis SLNCT07179237 Efficacy of Carminal in Helicobacter Pylori GastritisH Pylori Gastritis; H Pylori Infection; H Pylori Eradication; Gastritis Associated With Helicobacterrecruiting80
2026-07 est.P2Saptalis Pharmaceuticals LLCNCT07146217 Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial InfectionBacterial Infectionsnot yet recruiting30
2026-06-29P3Vivacelle BioNCT06072430 A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)Septic Shock; Sepsis; Hypovolemiacompleted39
2026-06-06P3Colgate Palmolive CLNCT07471477 Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard ToothbrushBacterial Load Reductioncompleted56

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "bacterial infections"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.